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ABSTRACT
Characterization of Sympathetic Ganglion Sensitivity to Substance P in a Genetic
and a Non-Genetic Rat Model of Hypertension
by
John Daniel Tompkins
Intravenous injection of substance P (SP) stimulates sympathetic ganglia to evoke a greater
increase in renal sympathetic nerve activity, heart rate (HR) and blood pressure (BP) in
hypertensive than normotensive rats due to upregulation of the NK1 receptor. These experiments
were designed to determine the cellular basis for the enhanced ganglionic responsiveness to NK1
agonists in spontaneously hypertensive rats (SHR) in comparison to their normotensive
counterparts, Wistar-Kyoto rats (WKY). Studies were also conducted to determine whether the
increased ganglion responsiveness to SP in SHR is causally related to the increased BP or is a
unique characteristic of this model of essential hypertension. Nerve recordings were made from
the external carotid branch of the superior cervical ganglion (SCG) in pentobarbital anesthetized
rats. Animals were treated with the ganglion blocking agent chlorisondamine (10.5 µmol/kg)
and pre- and postganglionic SCG nerves were cut. SP (1.0 to 100 nmol/kg) evoked a greater
increase in postganglionic nerve firing from the SCG of SHR vs. WKY. Intracellular
microelectrode recordings were made from isolated SCG. Membrane properties were similar
between strains. Picospritzer application of the NK1 agonist GR-73632 (100 µM, 1 s) caused
slow depolarization and increased neuron excitability. Depolarization amplitude and duration
were similar between strains, however, a greater percentage of neurons were depolarized by the
NK1 agonist in SHR. To determine if the ganglion sensitivity to SP was correlated with blood
pressure WKY were made hypertensive by unilateral nephrectomy and deoxycorticosterone
acetate (DOCA)/salt treatment. Tail cuff BP was the same in treated WKY and untreated SHR.
Increases in sympathetic nerve activity, HR and BP in response to SP (1.0 to 100 nmol/kg) were
the same in treated and untreated WKY rats. In conclusion, SHR are more responsive to
ganglion stimulation by NK1 agonists due to a greater number of responsive cells within their
SCG rather than an enhanced responsiveness of individual neurons. The increased sympathetic
nerve responsiveness to SP is an inherent characteristic and not an adaptive response of
sympathetic ganglion neurons to hypertension. This enhanced action of SP at sympathetic
ganglia may contribute to the elevated sympathetic outflow observed in this model of
hypertension.
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CHAPTER 1

INTRODUCTION
Increased sympathetic outflow plays an major role in the development and maintenance of
high blood pressure in spontaneously hypertensive rats (SHRs) ( Bunag et al. 1975; Folkow
1975; Judy et al. 1976; Judy and Farrell 1979; Folkow 1982; Oparil 1986; Oparil et al. 1989;
Ferrario and Averill 1991; Kumagai et al. 1992). Increased peripheral sympathetic output is also
observed in humans with essential hypertension (Folkow 1975; Folkow 1982; Mark 1996). The
increased sympathetic activity can raise blood pressure through stimulation of the heart, the
peripheral vasculature, and the kidneys, causing increased cardiac output, increased vascular
resistance, and fluid retention. Several mechanisms believed to underlie the increased nerve
activity have been proposed but fail to accurately explain this condition in either scenario.
Recent evidence suggests that abnormal neurotransmission through sympathetic ganglia may
contribute to the elevated sympathetic tone in hypertensive rats (Magee and Schofield 1992;
Magee and Schofield 1994). Multiple neuroactive substances function at the level of autonomic
ganglia to modulate ganglion output to the periphery (Heym et al. 1991; Elfvin et al. 1993;
Gibbins et al. 2000). Among these agents substance P, a sensory neuropeptide, has an excitatory
effect on neurons of sympathetic ganglia (Dun and Karczmar 1979; Jiang et al. 1982; Konishi
and Otsuka 1985). Substance P containing sensory nerve fibers innervate the peripheral
vasculature (Malliani 1982; Dalsgaard et al. 1983; Holzer 1998; Holzer and Maggi 1998) and
collaterals of these fibers innervate sympathetic ganglia (Oldfield and McLachlan 1978; Konishi
et al. 1985; Cuello 1987; Quigg et al. 1990). This circuitry may thereby constitute a peripheral
reflex mechanism for the regulation of cardiovascular function (Konishi et al. 1985; Mantyh
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1991; Elfvin et al. 1993). Sympathetic ganglia of hypertensive rats show an enhanced
responsiveness to substance P as compared to their normotensive counterparts (Hancock and
Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al. 2000). The increased sympathetic
nerve activity in response to intravenous administration of substance P raises blood pressure in
SHRs (Schoborg et al. 2000). This evidence suggests substance P is involved in the increased
sympathetic drive of hypertensive rats by enhancing ganglion outflow and may thus be involved
in the elevation of blood pressure observed in this strain. This work investigated the cellular
mechanism of the enhanced ganglion excitability to substance P and examined whether this
phenomenon is correlated with the increased blood pressure or is a causative factor in the
development of hypertension in SHRs.
Hypertension and the SHR
Hypertension, the clinical term for high blood pressure, is the most common cardiovascular
disease in the United States (American Heart Association 2001). Approximately 24% of all
adults in the United States have high blood pressure. Patients are conventionally considered
hypertensive when they have a diastolic blood pressure at or above 90 mm Hg, a systolic blood
pressure at or above 140 mm Hg, or both after repeated determinations (American Heart
Association 2001). This helps to characterize a group of individuals who are at risk of
developing hypertension-related cardiovascular disease. While acute elevation of blood pressure
is not associated with high mortality, long-term elevation of arterial pressure contributes to
pathological changes in the vasculature and myocardium. These changes are associated with
increased risk of stroke, disease of the coronary arteries, which can lead to myocardial infarction
or sudden cardiac death, and can be major contributors to cardiac failure, renal insufficiency and
dissecting aneurysm of the aorta (Oates 1996).
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Hypertension can be categorized as primary or secondary dependant on the cause. With
secondary hypertension an elevated blood pressure develops due to a known underlying
pathological condition. Pheochromocytoma is an example of secondary hypertension in which a
chromaffin cell carcinoma secrets excess catecholamines, evoking sympathetic hyperactivity.
Primary or essential hypertension is by far the most common form of hypertension in humans,
accounting for more than 95% of all observed cases (Oparil 2000). In contrast to secondary
hypertension, the underlying cause of essential hypertension is unknown. Essential hypertension
is known to cluster in families and most likely represents a collection of genetically based
diseases or syndromes with a number of resultant inherited biochemical abnormalities (Oparil
2000). Many pathophysiological factors have been implicated in the genesis of essential
hypertension, including increased sympathetic nervous system activity, over-production of
sodium-retaining hormones and vasoconstrictors, increased activity of vascular growth factors,
and altered cellular ion transport (Oparil 2000). Environmental factors (i.e. smoking, stress,
poor diet) contribute significantly to the progression of the disease, and primary hypertension
ultimately manifests in structural changes of the heart and vasculature that contribute to the
maintenance of the elevated arterial pressure (Oparil 2000).
The SHR is the most widely studied animal model of hypertension and is considered an
acceptable model for human essential hypertension given their genetic predisposition to
hypertension and the similar pathophysiological development of the disease (Yamori and
Okamoto 1974; Lovenberg 1986; Mulvany 1992; Pinto et al. 1998). As in human patients with
essential hypertension, SHRs also exhibit a polygenic predisposition to the development of
hypertension (Louis et al. 1969), environmental factors contribute to the progression of the
disease and a structural upward resetting of the heart and vessels occurs in response to the
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elevated arterial pressure and sustains the elevated blood pressure (Yamori et al. 1979; Yamori
1989; Yamori 1991; Folkow 1993).
SHRs were developed in 1963 at the Kyoto Institute from outbreed Wistar (Okamoto 1969;
Okamoto et al. 1973). Rats that displayed an elevated arterial blood pressure were cross breed
and offspring from these pairs were selected for “spontaneous” development of hypertension.
Subsequent interbreeding has resulted in a strain of rats with phenotypic homology that provide
standardized, handy and time-compressed caricatures for the investigation of essential
hypertension.
Autonomic Control of Blood Pressure
The cardiovascular system is regulated by a complex hierarchy of feedback-regulated control
systems with considerable overlap in the regulation of vascular pressure. The autonomic nervous
system plays a central role in the regulation of blood pressure on a short-term basis with its
ability to rapidly and profoundly modify cardiovascular function. The excitatory effects of
sympathetic innervation are balanced by the inhibitory parasympathetic inputs at multiple
tissues. At rest the cardiovascular system is a closed-loop pressure-regulated system. Basal
vascular tone is maintained by sympathetic innervation. Increases in sympathetic drive to the
heart and periphery increase the rate and force of myocardial contraction and increase peripheral
vascular resistance. Blood pressure, the product of cardiac output and peripheral vascular
resistance, is subsequently elevated. The increased vascular pressure activates pressure sensitive
cells or baroreceptors that “feedback” to the central nervous system to attenuate sympathetic
drive. In this way basal vascular tone is maintained near normal physiological values on a beatby-beat basis. These nervous control mechanisms are ideally suited for short-term circulatory
control while renal excretory functions are believed to be the primary regulators of blood
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pressure in the long term (Guyton 1980). In addition to neuronal connections to autonomic
effector tissues, neuroendocrine control mechanisms also modulate blood pressure but operate
more diffusely and generally have a slower time course. The renin-angiotensin-aldosterone
system participates in short- as well as long-term blood pressure control by influencing renal
sodium absorption and by direct and possibly centrally mediated effects on blood vessels (Baum
1990).
Sympathetic Neuroanatomy
The general components of the sympathetic innervation of the heart and vasculature are well
understood. Autonomic outflow from the CNS originates from “centers” (i.e., nuclei or more
diffusely arranged groups of cells) in the brainstem and hypothalamus. These regions are closely
related and are subject to excitatory and inhibitory input from afferent fibers and from higher
brain structures. Neural tracts originating from medulla and hypothalamus descend the spinal
cord and innervate, directly or via interneurons, cell bodies of the majority of preganglionic
sympathetic neurons located in the intermediolateral column of the thoracolumbar spinal cord
(Baum 1990; Randall 1994).
The efferent division of the sympathetic part of the autonomic nervous system is structurally
organized as a two-neuron pathway from the central nervous system to the peripheral effector
organ (Fig. 1). Preganglionic sympathetic neurons targeting the heart are located in the lower
cervical and upper thoracic segments of the spinal cord. Nerve fibers from these cells project to
the ganglion cell bodies of the upper thoracic ganglia and form axodentric synapses with the
postganglionic cell membrane. Unmyelinated postganglionic nerve fibers then project from the
ganglion cell bodies to multiple tissues (Randall 1994). Stimulation of sympathetic nerves
innervating nodal tissue, conduction tissue and the myocardium increase heart rate, conduction
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velocity and myocardial contractility. These effects are mediated by a release of norepinephrine
at the target site.
A large portion of the sympathetic nervous system is concerned with distributing electrical
signals that initiate and maintain the degree of constriction of blood vessels throughout the body
(McLachlan 1995). Most blood vessels are richly innervated by sympathetic fibers. However,
the density of innervation of individual arteries and veins varies considerably. Postganglionic
nerve fibers from sympathetic ganglia form a network of anastomosing filaments that course the
periphery of vessels. Arteries typically receive a greater density of innervation than veins
however this density can vary considerably. Stimulation of sympathetic nerves or intraarterial
injection of norepinephrine results in vasoconstriction and an increase in vascular resistance.

FIG 1. Schematic illustration of sympathetic innervation of the heart and vasculature.
Preganglionic efferent sympathetic neurons converge on postganglionic neurons at sympathetic
ganglia. Preganglionic neurotransmission is cholinergically mediated via nicotinic receptors.
Postganglionic adrenergic neurons release norepinephrine at peripheral arterioles and heart to
mediate vasoconstriction and tachycardia respectively. Stretch activated baroreceptors within
carotid sinus and aortic arch attenuate central sympathetic neurochemical drive.
14

Ganglionic Neurotransmission
The intervening ganglia within this two-neuron pathway have classically been viewed as
simple relay stations; however, it is currently understood that autonomic ganglia represent
important peripheral control centers whereby central neurochemical input can be modulated to
more effectively meet the demands of the target tissue. Here a heterogeneous population of
neuroactive elements function to modulate ganglionic output to the periphery (Lundberg and
Hökfelt 1986; Elfvin et al. 1993; Gibbins and Morris 2000; Gibbins et al. 2000). In addition to
the classic innervation by acetylcholine containing preganglionic nerve fibers, paravertebral
sympathetic ganglia receive a diverse input from peptidergic, noradrenergic, aminergic and nitric
oxide containing nerve fibers (Hökfelt et al. 1975; Hökfelt et al. 1977; Dalsgaard et al. 1982;
Mantyh et al. 1992; Elfvin et al. 1993; Gibbins and Morris 2000). The noradrenergic innervation
may arise from interganglionic neurons or postganglionic neurons in adjacent ganglia (Baum
1990). The peptidergic innervation originates from preganglionic fibers originating in the
intermediolateral column of the spinal cord (Jimenez et al. 2002) and from peptide containing
axon collaterals of dorsal root primary afferents (Oldfield and McLachlan 1978; Konishi et al.
1985; Cuello 1987; Quigg et al. 1990).
Neurotransmission at the ganglia has long been realized to be more complex than that
described by a single neurotransmitter-receptor system. Intracellular recordings from ganglion
neurons reveal at least four different types of synaptic events evoked by stimulation of
preganglionic nerve fibers (Volle and Hancock 1970; Dun and Karczmar 1979; Weight et al.
1979; Dun 1980). The primary event is a fast excitatory postsynaptic potential (EPSP) that
involves a rapid depolarization of the postsynaptic membrane by acetylcholine. This response is
mediated by ganglion nicotinic receptors. The secondary events are believed to modulate this
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primary event. The secondary events are insensitive to hexamethonium or other nicotinic
antagonists. They include the slow EPSP, late slow EPSP, and an inhibitory postsynaptic
potential (IPSP). The slow EPSP is mediated by agonists at muscarinic receptors and is blocked
by antagonists that are selective for M1 muscarinic receptors (Libet 1970). The IPSP is believed
to be mediated by the release of catecholamines from interneurons by acetylcholine (Dun 1980;
McAfee et al. 1980). The late slow EPSP can last for several minutes and is initiated by the
action of peptides, including substance P, released within the ganglia (Dun and Karczmar 1979;
Dun and Jiang 1982; Konishi and Otsuka 1985; Szucs et al. 1999).

Enhanced Sympathetic Nerve Activity in Hypertension
Multiple lines of evidence support a role of the sympathetic nervous system in the
pathogenesis of hypertension in hypertensive rats (Okamoto et al. 1967; Okamoto 1969; Folkow
1975; Judy et al. 1976; Schramm and Chornoboy 1982; Howes 1984; McCarty 1986; Jubelin and
Kannan 1990; Mark 1996). Both indirect and direct assays of sympathetic nerve activity
demonstrate increased sympathetic outflow. Norepinephrine turnover is increased in systemic
vascular tissues (Yamori et al. 1972) and plasma catecholamine and dopamine-beta-hydroxylase
activity are elevated (Yamori et al. 1972; Roizen et al. 1975). Microneurography, a technique
using microelectrodes to directly measure peripheral or muscle sympathetic nerve activity, shows
elevated sympathetic nerve activity in anesthetized and conscious SHRs (Okamoto et al. 1967;
Judy et al. 1976; Schramm and Chornoboy 1982). In addition to increased basal sympathetic
outflow, SHRs also display a sympathetic hyperresponsiveness to stressful stimuli (Yamori et al.
1969; Koepke et al. 1987) and hypothalamic stimulation (Bunag and Takeda 1979). Early
interference with sympathetic cardiovascular regulation prevents the development of the
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hypertension in the SHR (Clark 1971; Weiss et al. 1974; Schramm and Chornoboy 1982;
Kushinsky and Bell 1983; Lee et al. 1987) and arterial blood pressure is lowered to similar levels
in anesthetized WKY, Wistar and SHRs following blockade of preganglionic neurotransmission
(Hancock and Lindsay 1995; Hancock and Lindsay 2000).
The mechanism underlying the increased sympathetic tone has not been clearly defined, nor
is it understood at what level sympathetic tone is augmented. One suggestion is that
baroreceptor modulation of sympathetic control is either defective (Judy and Farrell 1979) or
inactivated by aberrant central neurochemical drive (Haeusler 1975). A lack of central
inhibitory input would enable tonically active peripheral sympathetic outflow as the systems errs
to maintain elevated arterial pressure. The hypothalamic centers where sympathetic outflow
originates have also been shown to be tonically active in SHRs (Yamori and Okamoto 1969).
Interestingly, abnormalities in the function of the peripheral autonomic ganglia may also be
involved in amplifying sympathetic output to the periphery. Transmission of neuronal activity is
elevated in sympathetic ganglia from hypertensive animals (Magee and Schofield 1992). Cyclic
nucleotide levels are also elevated in sympathetic ganglia suggestive of increased second
messenger activity (Ariano and Kenny 1987). It is uncertain whether the increased ganglionic
neurotransmission is due to a hyperexcitable postganglionic membrane, facilitation of
preganglionic neurotransmitter release or other factors modulating ganglion activity. An
increase in the stimulation induced release of, and hyperresponsiveness to, norepinephrine has
been shown at peripheral postganglionic nerve endings (Ekas and Lokhandwala 1981; Westfall
and Meldrum 1985). SHR ganglion neurons have also been shown to have hyperexcitable
membranes (Yarowsky and Weinreich 1985; Jubelin and Kannan 1990), a decreased
concentration of the inhibitory transmitter dopamine and an increased production of
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catecholamines in response to cholinergic stimulation (Lutold et al. 1979; Ariano and Kenny
1987; Debinski and Kuchel 1989). The postsynaptic effects of ACh are similar between SHR
and WKY rat postganglionic neurons (Magee and Schofield 1995). One goal of this study was
to use basic intracellular microelectrode recording techniques to investigate the active and
passive membrane properties of superior cervical ganglion (SCG) neurons from hypertensive and
normotensive animals. Recent studies have also suggested that endogenous substance P may
play a role at sympathetic ganglia to contribute to the heightened postganglionic sympathetic
nerve activity in SHRs (Gurusinghe and Bell 1989a; Gurusinghe and Bell 1989b; Hancock and
Lindsay 2000; Schoborg et al. 2000).

Substance P
The neuropeptide Substance P was first isolated from the equine gut and characterized based
on its ability to promote vasodilation in anesthetized rabbits (von Euler and Gaddum 1931).
Lembeck first proposed the idea that substance P may function as a neurotransmitter of primary
sensory neurons (Lembeck 1953). Isolation and sequencing of the peptide’s structure by Leeman
and colleagues helped clarify the role of this peptide in sensory neurotransmission (Chang et al.
1971). Substance P belongs to a family of structurally similar, fast-acting peptides termed
tachykinins. There are three major mammalian tachykinins; substance P, neurokinin A and
neurokinin B. Substance P and neurokinin A are processed from the same gene. A separate
gene encodes the neurokinin B peptide (Bonner et al. 1987; Nakanishi 1987; Krause et al. 1989).
There are three tachykinin receptor subtypes termed NK1, NK2 and NK3. NK1 receptors are
expressed in a wide variety of tissues including central nervous system neurons and vascular
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endothelial cells (Maggio 1988; Dam et al. 1988; Helke et al. 1990). Substance P has a 1000
fold higher affinity for NK1 receptors than neurokinin A or neurokinin B.

Substance P’s Involvement in Local Regulation of Blood Pressure
Substance P containing sensory nerve fibers project from dorsal root ganglia to the peripheral
vasculature as well as to the dorsal horn of the spinal cord whereby peripheral sensory
information is relayed to the central nervous system (Hökfelt et al. 1975; Dalsgaard et al. 1983).
Collaterals of the peripherally directed fibers also project to prevertebral (Hökfelt et al. 1977;
Dalsgaard et al. 1982; Cuello 1987; Matthews et al. 1987; Elfvin et al. 1993) or paravertebral
sympathetic ganglia (Gurusinghe and Bell 1989b; Quigg et al. 1990; Elfvin et al. 1993).
Stimulation of sensory collaterals to these ganglia or application of exogenous substance P elicits
slow depolarization of the postganglionic sympathetic neurons (Dun and Karczmar 1979;
Tsunoo et al. 1982); tachykinin receptor antagonists block the membrane response in both
experimental conditions (Konishi and Otsuka 1985). Accordingly, sensory afferents may release
substance P at sympathetic ganglia to modulate ganglion function (Dun and Jiang 1982; Konishi
et al. 1985; Cuello 1987). Substance P containing sensory afferents may likewise constitute a
peripheral reflex mechanism involved in the local control of blood pressure (Fig. 2).
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FIG 2. Hypothetical model illustrating short-loop reflex modulation of peripheral
sympathetic outflow by substance P containing sensory afferents. Sensory afferent fibers,
originating from dorsal root ganglia, innervate peripheral vasculature and central nervous
system to relay sensory information from the periphery to the CNS (Hökfelt et al. 1975;
Dalsgaard et al. 1983). Efferent-like collaterals to these fibers innervate peripheral arterioles
and sympathetic ganglia (Hökfelt et al. 1977; Dalsgaard et al. 1982; Malliani 1982; Dalsgaard
et al. 1983; Cuello 1987; Matthews et al. 1987; Elfvin et al. 1993; Holzer 1998; Holzer and
Maggi 1998). Release of substance P from these peripheral processes modulates ganglion
neurotransmission and evokes peripheral vasodilation (Dun and Karczmar 1979; Tsunoo et al.
1982; Holzer 1998; Holzer and Maggi 1998). This circuitry may hereby constitute short-loop
reflex arcs involved in the peripheral modulation of cardiovascular function.

Effect of Substance P In Vivo
Intravenous injection of substance P increases blood pressure and heart rate in rats (Hancock
and Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al. 2000). These responses are due
to stimulation of tachykinin receptors at sympathetic ganglia as they are blocked by adrenergic
receptor antagonists and unaffected by ganglion blockade or destruction of the brain stem and
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spinal cord (Hancock and Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al. 2000).
Substance P can stimulate NK1, NK2, or NK3 receptors but has greatest potency on NK1
receptors. Blockade of this receptor inhibits the pressor response to the ganglionic action of
substance P (Schoborg et al. 2000). These observations suggest that substance P modulates
sympathetic nerve activity and blood pressure and that the effect is mediated by NK1 receptors.
Also supporting the role of tachykinins in the control of blood pressure is the observation that
afferent fiber denervation by chronic exposure to the sensory nerve toxin capsaicin reduces
sympathetic drive to the heart and peripheral vasculature (Virus et al. 1981; Lembeck and
Skofitsch 1982).
In addition to its action on sympathetic ganglia, substance P causes vasodilation (von Euler
and Gaddum 1931) by a direct action on endothelial NK1 receptors (Maggio 1988) to release
endothelium-derived relaxant factor (Furchgott et al. 1984). The ganglionic stimulation caused
by substance P, however, appears to be able to override the vasodilator response with the result
that substance P increases blood pressure (Hancock and Lindsay 1995). Depletion of
catecholamines from peripheral nerves by reserpine blocks the pressor response and unmasks the
vasodilator response further demonstrating that the pressor response is due to the ganglionic
action of substance P (Hancock and Lindsay 1995).

Substance P’s Involvement in Hypertension of SHR
Several lines of evidence suggest that there is a selective increase in the action of substance P
on sympathetic ganglia of hypertensive rats and that the responsiveness of the ganglia to
substance P is correlated with blood pressure. SCG of genetically hypertensive rats are more
densely innervated by substance P-immunoreactive fibers than are ganglia from normotensive
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rats (Gurusinghe and Bell 1989a; Gurusinghe and Bell 1989b). Evidence from our laboratory
showed a three-fold increase in the expression of the NK1 receptor message and NK1 receptor
protein in SCG of SHRs (Schoborg et al. 2000). Furthermore, we showed that intravenous (i.v.)
injection of substance P or an NK1 selective agonist elicits enhanced renal sympathetic nerve
activity, tachycardia and a pressor response in SHRs. Conversely, in WKY rats substance P
causes vasodilatation and has minimal effects on sympathetic nerve activity (Schoborg et al.
2000).
While the sympathetic ganglia supplying the renal innervation in SHRs have an enhanced
sensitivity to i.v. administration of substance P (Hancock and Lindsay 1995; Hancock and
Lindsay 2000; Schoborg et al. 2000), it is unknown whether this is a unique feature of renal
sympathetic ganglia or a common occurrence of sympathetic ganglia in hypertensive animals.
Evidence of increased innervation of SCG by substance P containing nerve fibers, combined
with the observations of increased NK1 receptor protein and mRNA would suggest that these
ganglia also display an increased sensitivity to substance P. To test this hypothesis we made
extracellular recordings from a branch of the external carotid nerve to measure the increase in
SCG outflow to close arterial injection of substance P in hypertensive and normotensive rats.
These ganglia were selected because of the existing evidence from our lab showing an increased
expression of NK1 receptors and evidence from other labs showing an enhanced innervation by
substance P containing nerve fibers (Gurusinghe and Bell 1989b; Schoborg et al. 2000). These
ganglia are also easily accessible, easily isolated and easily removed for intracellular recording
experiments.
Intracellular recordings were made from SCG neurons to investigate the cellular mechanism
of the increased excitability of the ganglia to substance P. Intravenous injections of substance P
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evoke increased ganglion activity (Hancock and Lindsay 2000; Schoborg et al. 2000) and
substance P has been shown to depolarized sympathetic ganglion neurons (Dun and Karczmar
1979; Tsunoo et al. 1982). The cause of the enhanced ganglion excitability to substance P is
unknown. Tachykinin NK1 receptors are upregulated in sympathetic ganglia of hypertensive rats
(Schoborg et al. 2000). How this upregulation of receptors manifests as enhanced ganglion
stimulation to intravenous administration of substance P is unknown. It is possible that an
upregulation of NK1 receptors on individual neurons would elicit an augmented depolarization of
ganglion neurons in the presence of substance P. Or this may only increase the probability of
response to substance P and not affect the magnitude of the depolarization. In addition to
investigating the resting membrane properties of these cells to determine whether increased
membrane excitability contributes to the increased sympathetic outflow in hypertensive rats, we
also investigated the magnitude of the membrane depolarization in response to picospritzer
application of substance P and the NK1 selective agonist GR73632. These studies should
elucidate the cellular mechanism for the enhanced ganglion excitability to substance P.
Sympathetic afferent fibers in blood vessels respond to a variety of stimuli, including pressor
drugs, arterial occlusion, changes in venous return and mechanical distension, by increasing their
firing (Malliani 1982). As previously mentioned, fibers from dorsal root ganglion cells pass
centrally to the dorsal horns of the spinal column and peripherally to tissues innervated by
sympathetic nerves. Collaterals of peripherally directed afferent fibers also pass to autonomic
ganglia (Hökfelt et al. 1977; Dalsgaard et al. 1982; Cuello 1987; Matthews et al. 1987;
Gurusinghe and Bell 1989b; Quigg et al. 1990; Elfvin et al. 1993). The release of sensory
peptides from peripheral sensory nerve terminals has been shown for a variety of
pharmacological and physiopathological stimuli, and the concept that sensory fibers release
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transmitters at all terminals is well accepted (Cuello 1987). This pathway from peripheral
sensory endings to dorsal root sensory neurons and ganglia again raises the possibility that
sensory peptides can modulate ganglion function by short reflex loops not involving the central
nervous system (Fig. 2). This raises the possibility that the increased sensory innervation and
increased sensitivity of sympathetic ganglia to the stimulant action of substance P are adaptive
responses initiated by stimuli originating in the vasculature as a result of the elevated blood
pressure and/or other factors associated with hypertension. Alternatively, the changes associated
with ganglion substance P could be an inherent characteristic of SHRs. These two alternatives
will be systematically evaluated in this study using the deoxycorticosterone acetate (DOCA)/salt
treated rat as a model for hypertension of nongenetic origin and SHR as a model for hypertension
of genetic origin. If the increased ganglion neuronal responsiveness to substance P is an inherent
trait of SHRs then it would not be expected to occur in rats with a nongenetic form of
hypertension. This reasoning is based on the working hypothesis that if the increased
responsiveness in SHR is secondary to the development of hypertension then it would be found
in rats with hypertension of non-genetic as well as genetic origin. Knowing this is fundamental
to knowing whether substance P is a causative factor in the development of hypertension or a
consequence of the hypertension.
In, summary, several lines of evidence converge to indicate that feedback modulation of
cardiovascular function is mediated by substance P at sympathetic ganglia and inherent
differences in this modulation may be important in the development or maintenance of
hypertension. Our working hypothesis is that the increased responsiveness of SHRs to
tachykinins is due to an upregulation of tachykinin receptors at sympathetic ganglia and that this
is an inherent characteristic of SHRs. The following goals will be addressed;
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Goals of this Study
I. Investigate the excitatory effect of substance P on postganglionic output from the superior
cervical ganglia in SHR and WKY rats. Extracellular recordings were made from a
postganglionic nerve of the SCG to determine effects of i.v. substance P on postganglionic firing.
II. Compare the effects of a selective NK1 agonist on the active and passive membrane
properties of individual superior cervical ganglion neurons from SHR and WKY rats.
Intracellular microelectrode recordings were used to determine if there was a greater response of
individual neurons in the SCG to the selective NK1 agonist GR-73632. This was done to
determine the basis for the enhanced responsiveness of sympathetic ganglia in SHRs to
substance P. Passive and active membrane properties of individual SCG neurons were also
investigated between hypertensive and normotensive animals.
III. Determine if making WKY rats hypertensive by DOCA-salt treatment results in an upregulation of NK1 responses compared to untreated age-matched SHRs. These experiments were
conducted to test the postulate that the increased sensitivity of sympathetic ganglia to the
stimulant action of substance P is an inherent characteristic of SHRs and not an adaptive
response to the hypertension.
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CHAPTER 2

MATERIALS AND METHODS
Source of Animals
The first series of extracellular nerve recordings and all intracellular experiments were
performed with male Harlan (Indianapolis, IN), SHR and WKY rats (12 to 14 weeks old). These
rats were purchased at 10 weeks of age and allowed to acclimatize 1-2 weeks prior to each
experiment.. Male 4-week-old SHR and WKY rats were purchased from Charles River
laboratories (Wilmington, MA) for the experiments involving DOCA/salt treated animals and
age matched SHRs.
All animals were housed individually at 24oC on a 12 hr light/dark cycle in the university’s
animal care facility. Animals, except those treated with DOCA/salt, received normal tap water
and rat chow ad libitum. All experiments were conducted in accordance with NIH Guidelines
for the Care and Use of Laboratory Animals. Experimental protocols were reviewed and
approved by the University Animal Care Committee.

In Vivo Studies
General Methods
Twelve- to 14-week-old animals were anesthetized with 32 mg/kg sodium/pentobarbital and
50 mg/kg ketamine by intraperitoneal (i.p.) injection. Anesthesia was supplemented as needed
by intravenous (i.v.) injection of 1.5 mg/kg sodium/pentobarbital. The trachea was cannulated to
facilitate respiration. The left femoral vein was cannulated for i.v. delivery of drugs. Blood
pressure was recorded from the femoral artery via a cannula connected to a Gould Statham
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pressure transducer and a Gould Brush 2400S polygraph (Cleveland, OH). Heart rate was
derived from the pressure pulse signal by a Gould ECG/Biotach amplifier. Body temperature
was monitored rectally with a thermistor probe and maintained at 37o C with a thermostatically
controlled heating pad. The left internal and external carotid arteries were ligated to direct
carotid blood flow to the superior cervical ganglia. The pre- and postganglionic sympathetic
nerves were cut reducing the possibility that nerve responses to substance P were mediated by
stimulation of the central nervous system or preganglionic nerve fibers. A branch of the external
carotid nerve was isolated, stripped of connective tissue and placed over bipolar, silver chloride
electrodes. The preparation was sealed with Quick-Cast (World Precision Instruments; Sarasota,
FL).

FIG. 3. Schematic illustration of the equipment used for recording extracellular nerve
activity. Raw nerve activity is recorded in a grounded Faraday cage providing isolation from
electromagnetic interference. First stage amplification is performed the cage near the signal
source. The amplified signal is serially connected to an oscilloscope for visualization, to a
polygraph recorder for second stage amplification and graphic translation and to a computer for
data acquisition and analysis.
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Extracellular Nerve Recording
Nerve activity was recorded using a bipolar silver electrode (Ø = 0.008''). The electrode was
connected to a Grass model P55 pre-amplifier using a shielded input cable. At the amplifier raw
nerve activity was bandpass filtered (30 Hz - 3 KHz) and amplified (gain = 100). This amplifier
provides signal conditioning and amplification near the signal source reducing the problem of
noise and cable capacity effects on the high impedance signal source. The amplifier signal
output was viewed on a Tektronix oscilloscope (model 5110) and relayed to a Gould Isolated
Preamp (model 18-5407-58, gain = 30) and a Gould Universal Amplifier (model 13-4615-58,
gain = 10) for secondary amplification. Total signal gain was 30,000x. A permanent record of
nerve activity was made on paper by a Gould 2400S polygraph recorder. The serial connections
made and the equipment used are illustrated in figure 3.
The amplified nerve signal was further relayed to an analog-to-digital converter for digital
data acquisition and analysis using a Pentium-1(200 MHz) based IBM compatible personal
computer. The analog data stream was sampled at 2 KHz with 14-bit resolution using
Strawberry Tree’s Flash-12 data acquisition board and the Workbench for Windows software.
Data from the sampled waveform were stored directly to the computer hard disk for future
analysis.

Data Analysis
Recorded data were replayed and analyzed with a program we designed using the
Workbench for Windows software. The percent change in nerve firing was calculated after
intraarterial injection of drugs. To calculate the percent change in nerve activity, the sampled
signal must first be broken into discrete blocks of time and the power of each segment was then
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calculated. Power analysis was done using the Fast Fourier Transform (FFT). This method has
previously been reported in the literature as an acceptable means to quantify changes in nerve
activity (Hancock and Lindsay 2000; Schoborg et al. 2000). The FFT is based on Fourier’s
theorem that every periodic signal can be decomposed into a series of harmonic functions, or
more simply, any shape wave can be represented by a sum of many harmonic waves. The FFT is
an adaptation of Fourier’s theorem useful for rapid computation of discrete (time limited)
waveform frequency components. Power spectrum output from the FFT graphs the “power”,
which is proportional to the square of the amplitude, versus the frequency for each sinusoidal
component in the sampled waveform. Thus the signal is expressed graphically with frequency
represented on the x-axis versus voltage on the y-axis. This representation of a neurogram or
nerve recording is termed the autospectrum.
For FFT analysis, data were organized into sequential blocks of time containing 2048
samples. At a sampling frequency of 2 KHz this corresponds to a sample time of 1.024 seconds.
It is essential that this bin or block size be a power of two for the FFT. These blocks of data
were then analyzed by FFT analysis. The resulting power spectrum for a sample bin is shown in
figure 4. The total power for each block is summated to give the total area under the curve by
integration (Fig. 5).
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FIG. 4. Power spectrum output from Fast Fourier Transform (FFT). One-second bins of
digitized data from the sampled waveform (sampling rate = 2 KHz) were analyzed by FFT.
Output from the FFT graphically depicts waveform power (Volts2) as a function of waveform
frequency. This spectrum is an analysis of nerve activity recorded from the external carotid
nerve in a spontaneously hypertensive rat. This bin depicts the peak nerve response to 32
nmol/Kg substance P.

FIG. 5. Integral of the power spectrum from figure 4. Power across all frequencies from the
output of the Fast Fourier Transform was summated by integration. This figure shows the
magnitude of the waveform power summated from low to high frequency for one bin of data (t =
1.024 s).
30

Total power for each block or time segment is then plotted continuously on the digital chart
recorder beneath the nerve signal as shown in figure 6. The percent increase in total power is
calculated as the percent increase of peak power from baseline. The baseline measurement is
taken as the stable power of nerve activity prior to administration of drugs (Y1 in Fig. 6). The
peak measurement is taken at the plateau of the increased power after drug administration (Y2 in
Fig. 6). These values are reported for the changes in nerve firing evoked by intraarterial
injection of drugs.

FIG. 6. Calculation of the percent change in nerve activity. Upper tracing is representative
of the digitized waveform acquired with bipolar silver electrodes from the external carotid nerve
of a spontaneously hypertensive rat. This tracing depicts the nerve response to intraarterial
injection of substance P (SP). Upper arrow marks injection artifact. The lower tracing plots the
maximum power for each sequential bin of sampled data. Vertical dashed lines indicate the time
of the baseline power measurement (Y1) and the peak power measurement (Y2). Horizontal
dashed lines indicate the autospectoral power at each point (Y1 & Y2). The percent change in
nerve activity is calculated as the percent increase in power from baseline (Y1) to peak power
(Y2). This response illustrates a 1000% increase in nerve firing.
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Measurement of SCG Responsiveness to Substance P
Experiments were begun approximately one hour after completion of the surgery. Ganglion
nicotinic receptors were blocked by i.v. administration of chlorisondamine (10.5 µmol/kg)
reducing the possibility that the effects of substance P on blood pressure and heart rate were due
to actions involving preganglionic sympathetic fibers or the central nervous system and to
prevent reflex modulation of the cardiovascular response. Slow administration of
chlorisondamine (45 min) produces a complete blockade of the blood pressure and heart rate
increases to 1.0 µmol/kg of 1,1-dimethyl-4-phenylpiperazinium (DMPP) without causing an
acute autonomic crisis. Nicotinic receptor blockade by chlorisondamine persists for the duration
of the experiment as shown by the blockade of the ganglion response to DMPP immediately
following chlorisondamine administration and at the end of the experiment. The effects of 1.0,
3.2, 10, 32 and 100 nmol/kg doses of substance P on blood pressure, heart rate and external
carotid nerve firing are recorded and the resulting dose response curves are generated. Injections
of substance P began 30 minutes after administration of chlorisondamine, and the different doses
were given in random order at thirty-minute intervals. The 100 nmol/kg dose of substance P was
always given last. We have previously shown that tachyphylaxis to substance P does not occur
with this regimen (Hancock and Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al.
2000).

DOCA/salt Hypertension
Unilateral Nephrectomy. Six-week-old WKY rats were randomly assigned to one of two
treatment groups; DOCA or SHAM. DOCA animals were unilaterally nephrectomized. Surgical
procedures were performed in a room dedicated to small animal survival surgery where aseptic
technique was utilized. Animals were anesthetized by combined i.p. injection of ketamine (45
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mg/kg) and xylazine (10 mg/kg). A 2 cm dorsal midline incision was made with its cranial
terminus at the level of the 13th rib. The abdominal wall was opened 1.5 to 2 cm lateral to the
spine. With blunt forceps the left kidney was seized and retracted through each incision. Care
was exercised to minimize disturbance of the adrenal gland. The left renal artery, vein and ureter
were ligated with 2-0 absorbable Vicryl suture and cut distal to the ligature to remove the kidney.
The abdominal muscle was approximated with 4-0 absorbable Vicryl suture (Ethicon,
Somerville, NJ) and the skin was closed with 2-0 absorbable Vicryl suture. Post-operatively,
animals were put in clean cages with fresh bedding and the cages were placed on a heating pad
for eight hours. Sham nephrectomies were performed identically in all respects, with the
exception that no ligation took place and the kidney was replaced intact.
DOCA/salt Treatment. DOCA animals were made hypertensive by chronic treatment with
deoxycorticosterone-acetate (DOCA) and high salt diet. Three days after surgery DOCA rats
began to receive weekly subcutaneous (s.c.) injections of DOCA (30 mg/kg) suspended in
sesame oil (Sigma, ST. Louis, MO) and were switched to a 1 % NaCl solution in place of normal
tap water. SHAM rats received weekly s.c. injections of sesame oil alone and were given normal
tap water to drink.

FIG. 7. Schematic illustration of the RTBP2000 system and Gould 2400S chart recorder for
non-invasive heart rate and blood pressure measurement.
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Non-Invasive Tailcuff Plethysmography. Blood pressure, heart rate and weight were
recorded weekly from all animals. Heart rate and blood pressure were measured non-invasively
from conscious animals using the RTBP2000 system from Kent Scientific (Torrington, CT)
(Figs. 7 and 8). Animals were restrained in a cylindrical rodent restrainer equipped with a
thermostatically controlled heater (Kent Scientific). Animals were warmed to promote
vasodilatation in the tail. An occlusion cuff and piezoelectric pulse sensor were placed around
the base of the tail. Gain and positioning of the pulse sensor were adjusted until a pulse was
detectable. The occlusion cuff was inflated and the increased pressure occluded blood flow to
the tail ablating the pulse signal. The occlusion pressure was then gradually reduced to restore
perfusion of the tail. Systolic pulse pressure was read as the occlusion cuff pressure at which the
pulse signal returned (Fig. 8). Heart rate was derived directly from the pulse signal. Animals
were conditioned to the restrainer daily for two weeks before measurements were made. Three
measurements were made from each animal and the mean value was recorded. This technique
for chronically measuring systolic blood pressure from conscious animals is routinely cited in the
literature and has been shown to be an accurate means for following the development of
hypertension in DOCA/salt treated animals (Lamprecht et al. 1977; Basso et al. 1985; Anderson
et al. 1988; Kirchner et al. 1993; Kubo et al. 2000).
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FIG. 8. Tail cuff measurement of heart rate and blood pressure. Heart rate and blood
pressure are measured weekly from conscious DOCA, SHAM and SHRs by non-invasive tail cuff
plethysmography. Upper tracings are of the pulse signal and bottom tracings are occlusion cuff
pressure (mmHg). Occlusion cuff pressure is increased (1) to occlude the pulse signal. As the
pressure in the cuff is reduced (2), systolic blood pressure is read at the point the pulse signal
returns (3). Tracings on the left are from a SHAM rat. Systolic blood pressure for this animal
was 158 mmHg and heart rate was 330 beats/min. On the right, this DOCA rat (4 weeks after
DOCA/salt treatment) had a systolic blood pressure of 208 mmHg and heart rate of 340
beats/min.

Measurement of SCG Responsiveness to Substance P in DOCA/salt Treated Animals
Extracellular nerve recordings as well as intra-arterial blood pressure and heart rate
recordings were made from SHR, DOCA and SHAM rats at 12 to 14 weeks of age. The left
external carotid artery was cannulated with 20 gauge polyethylene tubing for close arterial
injection of DMPP and substance P to the superior cervical ganglia. Substance P was applied by
close arterial injection to minimize systemic effects of the peptide. Microinjection of 50 µl
substance P into the common carotid artery yields a similar ganglion response as i.v.
administration with a quicker onset.
In Vitro Studies
Intracellular Recording
Rats were anesthetized via i.p. injection of 50 mg/kg sodium/pentobarbital. The carotid
artery with attached SCG was removed from the anesthetized animals, placed in a custom
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recording chamber and continuously superfused with a modified Krebs solution (pH 7.38 – 7.40)
of the following composition (in mM): 120 NaCl, 25 NaHCO3, 1.1 NaH2PO4, 5 KCl, 11
Dextrose, 2 MgCl2, 2.5 CaCl2. Buffer was delivered to the chamber by gravity flow at the rate of
2 ml/min and continuously gassed with 95% O2/5% CO2. The temperature of the superfusate
was maintained at 34oC by a thermostatically controlled heater (Warner Instruments, Hamden,
CT). The SCG was separated from the carotid artery and pinned to the Sylgard (Dow Corning,
Midland, MI) floor of the chamber. Overlying connective tissue was teased away and pinned
around the ganglia for support. After one hour of equilibration, intracellular recordings were
made from superficial SCG neurons using standard microelectrode recording techniques.
Recordings were made with high impedance (60-80 MΩ) borosilicate glass micropipettes (Sutter
Instrument Co., Novato, CA) filled with filtered 3 M KCl. Transmembrane potentials were
recorded in a current clamp configuration using A-M Systems Neuroprobe amplifier (model
1600, Everett, WA). Before cells were impaled the reference potential was adjusted to zero, the
electrode resistance was nullified and the transmural capacity was compensated. Cells were
allowed to stabilize for about three minutes after impalement before membrane properties were
measured. Intracellular depolarizing and hyperpolarizing current pulses, triggered by a Grass
S88 stimulator (Quincy, MA) were given through the recording electrode. Intracellular current
and voltage signals were visualized on a Tektronix analog oscilloscope and on the monitor of a
Dell Dimension 200 MHz Pentium computer. The computer was equipped with Strawberry
Tree’s “Flash 12” analog to digital converter and Workbench software suite for data acquisition
and analysis (Kent Scientific, Litchfield, CT). GR-73632 ([100 µM], RBI, Natick, MA) was
applied in 1-second pulses through a 5 µm bore diameter micropipette by local pressure ejection
using a General Valve Picospritzer II (Fairfield, NJ).
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Data Analysis
Only neurons with stable resting membrane potentials more negative than - 40 mV were
included in the analysis. Cell input resistance was estimated from the slope of the line plotting
membrane potential displacements from resting membrane potential against the amplitude of a
series of hyperpolarizing pulses. Action potential duration was measured at two-thirds peak
amplitude. Afterhyperpolarization (AHP) duration was measured from the point at which the
repolarizing potential crossed the level of the resting membrane potential to the point at which
the potential had returned to one-half the peak amplitude of the AHP (Edwards et al. 1995; Smith
1999; Zhang et al. 2001). Only depolarizations evoked by GR-73632 that were equal to or
greater than 2 mV are to be included in the analysis. Depolarization durations were measured
from the onset of the depolarization to the point at which the potential returned to the resting
membrane potential or to the point at which the potential stabilized.

Source of Drugs
All drugs were diluted with saline. Rapid IV injection of 50 µl saline did not affect nerve
firing, blood pressure or heart rate. The drugs used and their sources were as follows:
sodium/pentobarbital (Abbott Labs, North Chicago, IL), ketamine (Fort Dodge, Fort Dodge, IA),
GR-73632 and substance P (RBI, Natick, MA), DMPP (Sigma, St. Louis, MO), chlorisondamine
was a gift from Novartus Pharmaceuticals Inc (East Hanover, NJ).

Statistical Analysis
Data values are expressed as mean ± SEM. GraphPad Prism software for windows
(GraphPad Software v.3.0, San Diego, CA) was used to perform one-way ANOVA and
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Newman-Keuls posttests on the means of the non-invasive measurements of heart rate and blood
pressure as well as weight among DOCA, WKY and SHR animals. Baseline values for heart
rate and mean arterial pressure in anesthetized animals were also compared this way.
Comparisons of mean arterial pressure (MAP) before and after ganglion blockade were made
with a students t-test (one-tail). Nerve, heart rate, and blood pressure responses to administration
of substance P were compared among treatment groups by GLM ANOVA and Fishers LSD post
tests using NCSS 97 (NCSS Statistical Software, Keysville, UT). Increases in heart rate, blood
pressure, and nerve firing were plotted as dose-response curves using GraphPad Prism version
3.00 software. P values <0.05 were considered significant.
For the intracellular studies, neuron membrane properties, action potential characteristics
and GR-73632 evoked depolarization amplitudes and durations were compared using an
unpaired t-test. Proportions of cells responding to GR-73632 within the SCG of hypertensive
and normotensive rats were analyzed with Chi-square analysis. Dependency of the AHP
amplitude with the cell input resistance was examined by correlation analysis. R squared (r2) is
given as the square of the correlation coefficient. P values <0.05 were considered significant.
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CHAPTER 3

RESULTS
In Vivo Studies
Measurement of SCG responsiveness to Substance P
Basal blood pressure and heart rate values were greater in SHRs than in WKY rats; however,
nerve firing was similar between strains. Prior to ganglion blockade, mean blood pressure was
101 ± 9 mmHg in WKY rats and 192 ± 10 mmHg in SHRs (p < 0.01), heart rate was 240 ± 17
beats/min in WKY rats and 305 ± 15 beats/min in SHRs (p < 0.01) and external carotid nerve
firing was 872 ± 209 µV2/s in WKY rats and 1,237 ± 472 µV2/s in SHRs. After treatment with
10.5 µmol/kg of chlorisondamine, mean blood pressure was 73 ± 8 mmHg in WKY rats and 88 ±
5 mmHg in SHRs, heart rate was 143 ± 6 beats/min in WKY rats and 158 ± 6 beats/min in SHRs
(p < 0.05) and external carotid nerve firing was 464 ± 82 µV2/s in WKY rats and 287 ± 22 µV2/s
in SHRs (p < 0.05).
Intravenous injection of substance P elicited dose-dependent increases in external carotid
nerve activity in SHRs and WKY rats (Figs. 9 and 10). Figure 9 shows increases in nerve firing
evoked by 32 nmol/kg substance P in a SHR and a WKY rat. The responses were significantly
greater in SHRs at 10, 32 and 100 nmol/kg doses (Fig. 10).
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FIG. 9. External carotid nerve, heart rate and blood pressure responses to i.v. substance P
(32 nmol/kg) in a SHR and a WKY rat. Arrows indicate time of injection.
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FIG. 10. Increased external carotid nerve firing in response to i.v. substance P (SP) in SHR
and WKY rats. There was a significant difference in the response between strains, (F (4,45) =
3.1, p < 0.05). * Significant difference between responses at the same dose. Number of rats is in
parentheses.

TABLE 1. Effect of Substance P (SP) on Blood Pressure and
Heart Rate in SHR and WKY Ratsa
Blood Pressure Change
(mmHg)
Dose SP
(nmol/kg)

Heart Rate Change
(bpm)

SHR

WKY

SHR

WKY

100

48 ± 5*
(4)

10 ± 2
(3)

50 ± 3*
(4)

16 ± 2
(3)

32

41 ± 5*
(6)

-1±3
(6)

83 ± 7*
(6)

52 ± 5
(6)

10

18 ± 2*
(6)

-6±3
(6)

62 ± 5*
(6)

24 ± 8
(6)

3.2

11 ± 2*
(6)

-7±3
(5)

53 ± 6*
(6)

15 ± 7
(5)

1.0

1 ± 2*
(5)

-7±2
(3)

31 ± 6*
(5)

2±4
(3)

a

Values are maximum changes in mean arterial pressure
or heart rate ± SEM after i.v. injection of substance P.
Number of animals contributing to means in parentheses.
* Significantly different from WKY at same dose.
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Blood pressure and heart rate responses to Substance P are reported as the maximum change
in heart rate or mean arterial pressure from baseline values. Substance P evoked dose-dependent
increases in heart rate and blood pressure in SHRs (Table 1). WKY rats respond with a dosedependent increase in heart rate but blood pressure was lowered. Responses to 32 nmol/kg
substance P are shown in figure 9. Heart rate and blood pressure changes were significantly
greater at all doses in SHRs.

DOCA/salt Hypertension
Non-invasive Tailcuff Plethysmography. Systolic blood pressure was significantly elevated
in 6-week-old SHRs compared to age matched DOCA and SHAM rats (153 ± 9 mmHg in SHR
(n = 12) vs. 123 ± 8 mmHg in DOCA (n = 12) and 116 ± 8 mmHg in SHAM(n = 14)). Blood
pressure gradually increased in DOCA animals over 6 weeks of DOCA/salt treatment (Fig. 11).
At 12 weeks of age, DOCA and SHRs had a similar degree of hypertension as indicated by
systolic blood pressure values measured by non-invasive tailcuff plethysmography (233 ± 10
mmHg in DOCA vs. 219 ± 9 mmHg in SHR). These values were significantly greater than those
from sham-treated animals at 8, 9, 10, 11, and 12 weeks of age. Heart rate was greater in DOCA
(389 ± 16 beats/min) and SHRs (409 ± 14 beats/min) in comparison to SHAM rats (349 ± 14
beats/min) at the end of treatment (Fig. 11). Weight gain was similar in DOCA and SHAM rats
from 6 to 9 weeks of age (Fig. 12). SHRs were significantly smaller than the other groups up to
10 weeks. At 12 weeks of age DOCA animals weighed significantly less (252 ± 6 g) than
SHAM (292 ± 5 g) or SHRs (286 ± 6 g).
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FIG. 11. Heart rate and blood pressure values recorded from SHAM, DOCA and SHRs.
Systolic blood pressure was recorded from conscious animals by non-invasive tail cuff
plethysmography. Comparisons were made by GLM ANOVA and post hoc analysis by NewmanKeuls test of means. Statistical significance at p < 0.05. Legend at right used for both figures. *
different from DOCA and SHAM, # different from DOCA and SHR, ** different from SHR and
SHAM.

300

Weight (grams)

#
#

**

#
200

*
#

*

**

SHR
SHAM
DOCA

*

*

100
5

6

7

8

9

10

11

12

13

Age (weeks)
FIG. 12. Recorded weekly weight for SHR, DOCA and SHAM animals. Comparisons were
made by GLM ANOVA and post hoc analysis by Newman-Keuls test of means. Statistical
significance at p < 0.05. * different from DOCA and SHAM, # different from SHR and DOCA,
** different from SHR and SHAM.
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Measurement of SCG Responsiveness to Substance P in DOCA/salt Treated Animals
Rats were anesthetized with i.p. injections of sodium pentobarbital (32 mg/kg) and ketamine
(50 mg/kg) for experiments involving extracellular nerve recording. Mean arterial blood
pressure (MAP) was significantly greater in SHRs (172 ± 7 mmHg, n = 12) than in DOCA (100
± 7 mmHg, n = 12; p < 0.01) and SHAM rats (112 ± 15 mmHg, n = 14; p < 0.01) after anesthesia
(baseline, Fig. 13). Heart rate was also significantly greater in this strain (315 ± 11 beats/min, n
= 12) in comparison to DOCA (193 ± 11 beats/min, n = 12; p < 0.01) and SHAM rats (236 ± 20
beats/min, n = 14; p < 0.01).
The selective ganglion nicotinic receptor agonist DMPP was administered prior to ganglion
blockade with chlorisondamine to test nerve activity. There was not a significant difference
between the percent increase in nerve activity between DOCA (6024 ± 1708 %), SHAM (6715 ±
1456 %) or SHRs (2195 ± 672 %) (F(2,24)=2.446, p > 0.05).
Chlorisondamine significantly lowered blood pressure in all three groups (Fig. 13). Blood
pressure was lowered to 64 ± 2 mmHg (n = 11, p < 0.01) in SHAM rats, 77 ± 5 mmHg (n = 11, p
= 0.03) in DOCA rats and to 74 ± 3 mmHg (n = 11, p < 0.01) in SHRs. Heart rate was also
significantly lowered from 247 ± 17 to 197 ± 22 beats/min in SHAMs (n = 11, p = 0.04) and
from 283 ± 13 to 174 ± 5 beats/min in SHRs (n = 11, p < 0.01). There was not a significant
change in the DOCA rat heart rate (193 ± 11 beats/min before, 191 ± 15 beats/min after
chlorisondamine; n = 11, p = 0.29).
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FIG. 13. Blood pressure before and after chlorisondamine. Anesthetized animals were
treated with the ganglion blocking agent chlorisondamine to prevent baro-reflex modulation of
heart rate and blood pressure. Mean arterial blood pressure (MAP) was significantly greater in
SHRs before chlorisondamine treatment. Chlorisondamine significantly lowered blood pressure
in all three treatment groups. After treatment, MAP was significantly less in SHAM animals
than either DOCA or SHRs. Comparisons were made using repeated measures ANOVA.
Statistical significance was observed at p < 0.05. * different from DOCA and SHAM at baseline,
# different from DOCA and SHR after chlorisondamine.

Substance P increased blood pressure in SHRs (Fig. 14). DOCA and SHAM animals did not
show a pressor response (Fig. 14). The dose dependency of the blood pressure response is
shown in figure 15. The three dose response curves were significantly different (F(2,4)=6.14, p
< 0.05). The magnitude of the pressor response was greater in SHRs at all doses tested (Fig. 15).
DOCA and SHAM animals responded similarly. In these animals substance P only elicited a
depressor response.
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FIG. 14. Polygraph tracings of the nerve, heart rate and blood pressure responses to intraarterial injection of substance P (SP) in an anesthetized SHAM, DOCA and SHRs. Rats were
treated with chlorisondamine (10.5 µmol/kg) to block nicotinic receptors in autonomic ganglia
and the pre- and postganglionic nerves were cut. Nerve responses are representative of mean
response for each group. Arrows indicate drug injection.
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FIG. 15. Change in arterial blood pressure to close arterial injection of Substance P.
Arterial blood pressure was recorded via cannulation of the femoral artery. Comparisons were
made by GLM ANOVA and post hoc analysis by Newman-Keuls analysis of means. Statistical
significance at p < 0.05. ** different from SHAM, * different from DOCA and SHAM, #
different from DOCA and SHR.

Close arterial injection of substance P elicited a dose dependant tachycardia in all animals
(Figs. 14 and 16). The three dose response curves were significantly different (F(2,4)=4.0, p <
0.05). The change in heart rate was less in DOCA animals than SHRs at 3.2, 10, 32 and 100
nmol/kg doses of substance P. The magnitude of the tachycardia was greater in SHAM
compared to DOCA rats at 10 and 32 nmol/kg doses of substance P. The 32 nmol/kg dose of
substance P elicited the greatest change in heart rate in all animals (Fig. 16). At this dose heart
rate was increased in SHAM rats from 197 ± 22 to 243 ± 24 beats/min (n = 11), in DOCA rats
from 191 ± 15 to 217 ± 17 beats/min (n = 11) and in SHR from 170 ± 4 to 249 ± 11 beats/min (n
= 10).
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FIG. 16. Change in heart rate in response to close arterial injection of substance P. Heart
rate was derived from the pressure pulse signal. Comparisons were made by GLM ANOVA and
post hoc analysis by Bonferroni test of means. Statistical significance at p < 0.05. ** different
from DOCA, * different from SHAM and DOCA, # different from SHR and SHAM.
Substance P elicited dose-dependant increases in external carotid nerve activity in each of the
treatment groups studied (Fig. 17). Figure 14 shows the increase in nerve firing evoked by 32
nmol/kg of substance P in a DOCA, SHAM and SHR. Nerve responses to substance P were
significantly greater in SHRs at 1, 10, 32, and 100 nmol/kg doses (Fig. 17). SHAM animals
responded greater than DOCAs to 32 nmol/kg substance P.
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FIG. 17. Increases in carotid nerve activity in response to close arterial injection of
substance P. Comparisons were made by GLM ANOVA and post hoc analysis by Bonferroni test
of means. Statistical significance at p < 0.05. * different from DOCA and SHAM, # different
from SHAM and SHR.

In Vitro Studies
Intracellular Recording
Membrane Properties of SCG neurons in SHR and WKY rats. Passive and active membrane
properties of SCG neurons are shown in Table 2. A total of 70 cells (28 animals) were sampled
from SHRs and 42 cells (16 animals) from WKY rats. With the exception of the amplitude of
the action potentials evoked by intracellular stimulation, which were slightly greater in WKY
rats than in SHRs, the membrane properties of these neurons were similar in the 2 strains.
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TABLE 2. Membrane Properties and Action
Potential Characteristics of SHR and WKY Superior
Cervical Ganglion Neuronsa
SHR

WKY

Resting
Membrane
Potential (mV)

- 49 ± 0.8
(70)*

- 50 ± 1
(42)

Cell Input
Resistance (MΩ)

63 ± 4
(68)

63 ± 6
(40)

Intracellularly Stimulated Action Potentials
Threshold
(mV)

- 39 ± 0.6
(70)

- 39 ± 0.8
(42)

Amplitude
(mV)

50 ± 0.7*
(70)

53 ± 1
(42)

Overshoot
(mV)

1.2 ± 0.6
(70)

2.5 ± 0.8
(42)

Duration
(ms)

1.7 ± 0.03
(70)

1.6 ± 0.05
(42)

AHP Amplitude
(mV)

16 ± 0.4
(69)

15 ± 0.5
(42)

AHP Duration
(ms)

102 ± 7
(69)

110 ± 8
(42)

a

Action potentials were evoked by intracellular
depolarizing currents delivered through the recording
electrode. Values are expressed as mean ± SEM.
Numbers of measurements contributing to means are in
parentheses.
* Significantly different from WKY.
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Neurons were characterized as phasic or tonic based on the firing pattern evoked by
intracellular depolarizing current pulses of 0.1-0.5 nA with a 1 second duration (Fig. 18). Cells
firing 2 or fewer action potentials were classified “phasic”. Cells that fired multiple action
potentials were classified “tonic”. There was no significant difference in the percentage of tonic
cells between hypertensive and normotensive animals. Twenty percent (14/70) of SHR SCG
neurons were tonic versus 17% (7/41) of WKY rat neurons. The cell input resistance (58 ± 3.6
MΩ (n = 88) vs 86 ± 7.5 MΩ (n = 18); p < 0.01) and the AHP amplitude (15 ± 0.3 mV (n = 89)
vs 18 ± 0.6 mV (n = 20); p < 0.01) were greater in tonic neurons than in phasic neurons from
both strains. There was no correlation between input resistance and AHP magnitude in tonic
cells (r2 = 0). Action potential amplitude and duration were similar in the 2 types of cells.

FIG. 18. Characterization of SCG neurons. A-B: top traces, transmembrane potential,
bottom traces, stimulus current. A: Phasic neuron; 1 second duration current pulse (0.53 nA)
evoked 2 action potentials (APs). Resting membrane potential - 45 mV. B: Tonic neuron; 1
second duration current pulse (0.48 nA) evoked multiple APs. Resting membrane potential was 54 mV. Vertical calibration bar: 15 mV. Horizontal calibration bar: 20 msec.

Membrane responses to GR-73632. Pressure application of the NK1-selective agonist GR73632 evoked a similar long lasting depolarization of SCG neurons in SHRs (Figs. 19 and 20)
and WKY rats. In SHRs, GR-73632 elicited a mean depolarization of 4.7 ± 0.5 mV. There was
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no significant difference in the percentage of tonic and phasic neurons that responded to GR73632. The duration of the depolarization was 49 ± 7 seconds (n = 22). In WKY rats, GR73632 elicited a depolarization of 4.5 ± 0.8 mV. The duration of the depolarization was 49 ± 6
seconds (n = 6). A long-lasting increase in membrane excitability accompanied the
depolarization in both strains. This is evidenced by the firing of anodal break action potentials at
the offset of the hyperpolarizing current pulses following GR-73632 application (Fig. 19). Only
a few cells (7/90) fired spontaneous action potentials in response to GR-73632 (Fig. 20). The
number of cells where GR-73632 caused firing was similar in SHRs and WKY rats. Substance P
had similar effects to those of GR-73632 on SCG neurons of SHRs and WKYs (data not shown).

FIG. 19. GR-73632 induced depolarization and increased membrane excitability of SCG
neurons. A: Transmembrane potential tracing from a SHR SCG neuron. GR-73632 (100 µM, 1
second pulse; indicated by arrow) elicited a 7 mV depolarization. Hyperpolarizing current
pulses applied at 1 Hz were used to elicit hyperpolarizing electrotonic potentials (downward
deflections). Vertical calibration bar: 5 mV. Horizontal calibration bar: 10 second. Resting
membrane potential was - 50 mV. B: Anodal break action potentials evoked by the offset of the
hyperpolarizing current pulse (0.2 nA; lower tracings) illustrate increase in membrane
excitability that lasted 50 second after GR-73632 application. Calibration bar from A: Vertical
scale: 10 mV. Horizontal scale: 35 msec.
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FIG. 20. Transmembrane potential response of a phasic WKY rat SCG neuron to GR-73632
(100µM, 1 second pulse). Twenty-five spontaneous action potentials occurred at the plateau of
the membrane depolarization (8 mV maximum amplitude, 67 second duration). Vertical
calibration bar: 5 mV. Horizontal calibration bar: 7.5 msec.

There was a significant trend for more SCG neurons to respond to GR-73632 in SHRs than in
WKY rats. Thirty-seven percent (22/59) of SCG neurons in SHRs were depolarized by GR73632 versus 19% (6/31) of WKY rats (p < 0.05; Fig. 21).
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FIG. 21. Percentage of WKY and SHR SCG neurons reponsive to GR-73632. A significantly
greater percentage of SCG neurons were depolarized by the NK1 agonist GR-73632 in SHR vs.
WKY rats (p < 0.05).
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CHAPTER 4

DISCUSSION
This study showed that stimulation of SCG tachykinin receptors by i.v. injection of substance
P causes a prominent increase in postganglionic nerve firing in SHRs. Blood pressure and heart
rate were also elevated. In contrast, substance P decreased blood pressure and only slightly
increased external carotid nerve firing and heart rate in WKY rats. Intracellular electrodes were
used to determine the cellular basis for the enhanced effect in hypertensive rats. Local
application of the NK1 receptor agonist GR-73632 evoked slow depolarization and increased
excitability of SCG neurons. These effects were similar in the two strains; however, there was a
significant trend for more neurons from SHRs to respond to the tachykinin agonist. These
observations suggest that the greater sympathetic nerve, blood pressure and heart rate responses
observed in response to ganglion stimulation of NK1 receptors in SHRs are due to a greater
number of sympathetic ganglion neurons expressing functional NK1 receptors rather than
differences in the effect of tachykinins on the membrane properties of sympathetic neurons. This
study also showed that changes in sympathetic nerve activity, heart rate and blood pressure in
response to substance P were similar between WKY made hypertensive by DOCA/salt treatment
and normotensive WKY. These results suggest that the increased sympathetic ganglion
responsiveness to substance P observed in SHR is not correlated with elevated blood pressure.

Characterization of Sympathetic Ganglion Responsiveness to Substance P in SHR and WKY
Increases in renal nerve firing, blood pressure and heart rate caused by substance P in SHRs
is due to stimulation of sympathetic ganglia (Hancock and Lindsay 2000). Those experiments
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utilized ganglion blockade to reduce the possibility that the effects of the tachykinins were due to
actions involving the central nervous system, and reserpine to eliminate the possibility that
responses were due to actions on peripheral tissues. In the present study, in addition to using
ganglion blockade, the ganglia were decentralized by sectioning preganglionic nerves. Thus,
increases in nerve firing recorded from the external carotid nerve were due to direct ganglion
stimulation. These observations also confirm the results from renal nerve recordings and suggest
that up-regulation of NK1 receptors is a characteristic of paravertebral ganglia in SHRs.
The predominant tachykinin receptor in sympathetic ganglia appears to be the NK1 type
(Seabrook et al. 1992; Zhao et al. 1993; Hawcock et al. 1995; Schoborg et al. 2000) and we have
shown that this receptor mediates the pressor response to substance P (Schoborg et al. 2000).
Other tachykinin receptor types may be present (Couture et al. 1989; Seabrook et al. 1992) but
do not appear to be necessary for the pressor response. Our preliminary studies showed that the
responses of individual neurons to GR-73632 and substance P produce similar effects on firing
from the SCG and on blood pressure indicating that the effects of substance P were due to
stimulation of NK1 receptors. A NK1 selective agonist was, therefore, used for intracellular
recording studies to increase the likelihood that its effects were on cardiovascular neurons. The
precise targets for specific neurons however were not determined.
The present study showed that more neurons responded to the tachykinins in SHRs than in
WKY rats. For the neurons that responded, the effects of substance P (data not shown) and GR73632 on the membrane potential and action potential characteristics were the same in the 2
strains. Although action potential amplitudes were slightly greater in ganglion neurons of WKY
rats than in those of SHRs, the biological significance of the differences is not known. Other
properties of the action potentials were similar in the 2 strains. Given these data, the increases in
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blood pressure and postganglionic sympathetic nerve firing likely reflect a greater number of
neurons in SCG excited by tachykinins in SHRs.
The effects of substance P to increase firing from the SCG are consistent with studies that
showed that substance P stimulated paravertebral ganglia to increase renal nerve firing and that
this effect was greater in ganglia of SHRs than those of WKY rats. In equimolar doses, the renal
nerve response to GR-73632 was less than the response to substance P in SHRs. The reason for
this difference was not clear but may be due to stimulation of NK2 and NK3 receptors by
substance P. This conclusion was supported by the observation that selective NK2 and NK3
receptor agonists have effects on renal nerve firing similar to those of substance P but of much
smaller magnitude (Hancock et al. 1998; Hancock et al. 1999). Responses to NK2 and NK3
receptor agonists were the same in SHR and WKY rats. Thus, the effect of substance P to
increase firing from the SCG probably represents activation of all three tachykinin receptors.
The contribution of stimulating NK2 and NK3 receptors however is the same in SHR and WKY
rats and they don’t appear to be involved in blood pressure regulation (Schoborg et al. 2000).
Active and passive membrane properties control AP generation and may regulate
neurotransmission (Burke 1987). Previous investigators have shown that SCG neurons from
SHRs lack spike accommodation and suggested that this may be responsible for the enhanced
basal sympathetic tone associated with the hypertension in this strain (Yarowsky and Weinreich
1985; Jubelin and Kannan 1990). No other differences in resting membrane properties were
observed between hypertensive and normotensive animals in those studies. In the present study,
we used similar methods to characterize neurons in the SCG of SHRs and WKY rats.
Application of a depolarizing current pulse to tonic cells elicited multiple action potentials at a
constant frequency. These cells lack any spike accommodation. We did not find a difference in
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either the basic membrane properties or the percentage of tonic cells between hypertensive and
normotensive rats. Accordingly, our results suggest that differences in the active and passive
neuronal membrane properties of the SHR alone do not account for the increased sympathetic
nerve activity observed in this strain. This conclusion is supported by experiments
demonstrating a disproportional pairing of synaptic input and output at high frequencies of
extracellular stimulation of the cervical sympathetic trunk in SHRs (Magee and Schofield 1992).
Compound action potential magnitudes, recorded from the internal carotid nerve, were
significantly greater in SHRs at low frequencies (1-80 Hz) of nerve stimulation whereas WKY
rats responded greater at high frequencies (80-100 Hz). If enhanced excitability of the
postganglionic cell membrane played a significant role in facilitating presynaptic transmission
then one would assume that synaptic transmission would be greater in SHRs across all
frequencies of nerve stimulation (Magee and Schofield 1992).
Studies have shown that sympathetic ganglia of SHRs are larger (Kondo et al. 1990) and
contain more sympathetic neurons (Messina et al. 1996) than ganglia of normotensive rats. This
raises the possibility that the enhanced ganglionic response to substance P in SHRs is due to a
greater number of neurons in ganglia of hypertensive rats. Our previous studies, however,
showed that the enhanced response to substance P does not seem to be due to a generalized
increase in sensitivity or cell number because renal nerve, blood pressure and heart rate
responses to DMPP were the same in SHRs and WKY rats (Hancock and Lindsay 1995).
Substance P and its receptors appear to be differentially regulated in various tissues of
hypertensive rats in a manner that is consistent with their involvement in hypertension. Kopp
and her associates (Kopp et al. 1998) have shown an impaired afferent renal nerve response to
increased pelvic pressure in SHRs due to either an impaired release of substance P or an
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impaired activation of substance P receptors. This impaired activation of renal sensory neurons
is believed to contribute to hypertension by increasing water and sodium retention. Decreased
circulating levels of substance P in SHRs and in humans with essential hypertension have also
been reported in the literature (Rathsack et al. 1983; Faulhaber et al. 1987). Since substance P
causes vasodilatation, the decreased circulating levels could contribute to the elevation of
peripheral vascular resistance. There is also an impairment of the peripheral vasodilator
response to substance P and other endothelium-dependant vasodilators which might tend to
enhance the effect of decreased circulating substance P (Pompei et al. 1993; Egashira et al.
1995). We have shown that substance P can increase sympathetic nerve activity and increase
blood pressure by an action on sympathetic ganglia (Hancock and Lindsay 1995; Hancock and
Lindsay 2000; Schoborg et al. 2000). Chen and coworkers have reported increased substance Plike immunoreactivity in the hypothalamus, in the rostral ventral surface of the medulla
oblongata and in the intermediolateral cell column of the thoracic spinal cord of SHRs (Chen et
al. 1990). These observations suggest the involvement of substance P in the central regulation of
vasomotor tone as another potential site of action for this peptide contributing to the
hypertension of the SHR. In context with the present observations, it is likely that substance P
and its receptor are involved in the pathogenesis of hypertension in SHRs.

Characterization of Sympathetic Ganglion Responsiveness to Substance P
in a Nongenetic Form of Hypertension
It is unknown whether the increased ganglion responsiveness to substance P observed in
SHRs is a unique characteristic of this model of hypertension or whether it is induced by the
elevated arterial pressure. Substance P containing sensory afferents innervate the peripheral
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vasculature and spinal cord and are known to relay peripheral sensory information to the central
nervous system. Collaterals to these fibers modulate ganglion function (Fig. 2). The afferent
fibers in blood vessels respond to a variety of stimuli, including pressor drugs, arterial occlusion,
changes in venous return and mechanical distension, by increasing their firing (Malliani 1982).
The increased sensory innervation and increased sensitivity of sympathetic ganglia to the
stimulant action of substance P observed in SHRs could, therefore, be an adaptive response
initiated by stimuli originating in the vasculature as a result of the elevated blood pressure.
DOCA/salt treated animals were used to investigate the effect of an induced increase in
arterial pressure on the ganglion responsiveness to substance P. Chronic DOCA/salt
administration evoked an elevated arterial pressure in WKY rats over the course of six weeks
with a similar time course of development as the hypertension observed in SHRs. Weekly noninvasive measurements of systolic blood pressure were made to monitor the progression of
hypertension in DOCA and SHRs. At 12 weeks of age, DOCA hypertensive rats did not show
increased ganglion responsiveness to substance P. Ganglion nerve activity, heart rate and blood
pressure responses to intraarterial injection of substance P were similar in DOCA treated and
control WKY animals. These results suggest that the observed increase in ganglion sensitivity to
substance P in SHRs is a unique trait of this genetic model of hypertension and is not causally
related to the increased arterial pressure.
Tail cuff monitoring of blood pressure is routinely cited in the literature as an accurate and
reliable means of non-invasive measurement of arterial pressure (Lamprecht et al. 1977; Basso
et al. 1985; Anderson et al. 1988; Kirchner et al. 1993; Kubo et al. 2000). Results from this
procedure demonstrated that arterial pressure of DOCA animals was significantly elevated over
controls from 8 through 12 weeks of age. However, after anesthesia with the barbiturate sodium
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pentobarbital, intraarterial blood pressure values were similar in DOCA/salt and sham treated
WKY rats and both were significantly lower than in SHRs. Further treatment with the ganglion
blocking agent chlorisondamine lowered blood pressure to similar values in SHR and DOCA rats
that were both significantly elevated from controls.
Why the conscious state mean arterial pressure was significantly higher in DOCA than
control rats before but not after pentobarbital anesthesia is unclear. Such sensitivity to
anesthetics in this kind of experimental hypertension has, however, previously been reported
(Iriuchijima et al. 1975; Iriuchijima et al. 1976). Pentobarbital has been shown to cause
hypotension, particularly at high doses (Wixson et al. 1987). This effect is partially mediated by
actions on the sympathetic nervous system. Pentobarbital suppresses central and peripheral
noradrenergic nerve activity (Takemoto 1992) and is associated with a significant reduction of
norepinephrine spillover and metabolic clearance (Maignan et al. 2000). As in the pathogenesis
of hypertension in the SHR, the importance of the sympathetic nervous system in DOCA/salt
hypertension is well documented (de Champlain et al. 1969; Iriuchijima et al. 1975; Takeda and
Bunag 1980; de Champlain et al. 1987; de Champlain et al. 1989). Central depletion of
catecholamines has been shown to prevent or reverse the hypertension in this model (Lamprecht
et al. 1977). Direct recordings from visceral sympathetic fibers also illustrate increased
sympathetic fiber activity (Takeda et al. 1988). Plasma catecholamines are also elevated
(Bouvier and de Champlain 1986). These findings suggest an important role of neural
mechanisms in maintaining DOCA hypertension. Why blood pressure wasn’t lowered in SHRs
to a similar degree is unknown but probably reflects differences in the pathways or mechanisms
for the hypertensive state between the 2 models.
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Chronic administration of DOCA induces sodium retention and, in the presence of a high salt
intake, produces a volume-dependant type of hypertension (de Gracia et al. 2000). The
pathogenesis of DOCA/salt hypertension is not fully understood but a number of consistent
features have been observed allowing for a generalized concept to be formed. Administration of
DOCA changes hormonal and neural pressor mechanisms. Relevant prehypertensive
mechanisms include increased activation of the brain renin-angiotensin system, increased
sympathetic nerve activity and a blunted baro-reflex response (Schenk and McNeill 1992). In
addition DOCA/salt hypertension induces characteristic changes in vascular structure and
reactivity that contribute to the overall pathology (Walker and Boyd 1983).
Intraarterial injection of substance P elicits a biphasic blood pressure response in rats
(Hancock and Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al. 2000). A transient
pressor response precedes a long-lasting depressor response. The increase in pressure is
mediated by stimulation of sympathetic ganglia while the depressor response is mediated by
stimulation of endothelial NK1 receptors. Kohlmann and colleagues have previously shown that
a selective NK1 antagonist raises blood pressure in DOCA/salt treated rats (Kohlmann, Jr. et al.
1995b; Kohlmann, Jr. et al. 1997). From these results they speculate that substance P expression
is elevated in DOCA/salt treated WKY rats as a counter regulatory mechanism to the elevated
arterial pressure (Kohlmann, Jr. et al. 1997). These results demonstrate that DOCA/salt
treatment may affect tachykinin expression. In the present experiments, intraarterial injection of
substance P lowered blood pressure in SHAM and DOCA rats to a similar extent over the range
of doses tested. Kohlmann suggests that the participation of substance P in the pathogenesis of
elevated BP could vary according to the phase of the hypertensive state and/or the experimental
model (Kohlmann, Jr. et al. 1995b). In their experiments they found that while substance P
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expression appeared to be upregulated during the benign or early phase of hypertension in
DOCA/salt treated rats the selective NK1 antagonist had no effect on blood pressure during later
phases (Kohlmann, Jr. et al. 1995a). Since the vascular responses were similar in treated and
untreated WKY, our results suggest we are looking at what they termed the malignant or more
advanced phase of DOCA/salt induced hypertension.
In conclusion, these studies showed that stimulation of NK1 receptors causes a greater
increase in postganglionic sympathetic nerve firing, blood pressure and heart rate in SHRs than
in WKY rats. This enhanced sympathetic ganglion responsiveness in SHRs appears to be due to
a greater number of neurons expressing NK1 receptors. This conclusion is based on results from
our studies with intracellular microelectrode recordings that showed that more neurons in the
SCG respond to NK1 receptor stimulation in hypertensive rats than in normotensive rats.
Further, the enhancement of the response does not appear to be due to a greater responsiveness
of individual neurons since NK1 receptor stimulation had similar effects on the membrane
properties of SCG neurons and in evoking firing from the neurons in the two strains. These
studies also showed that the postganglionic sympathetic nerve, heart rate and blood pressure
responses to substance P are similar in hypertensive and normotensive WKY rats. This suggests
that the enhanced ganglion responsiveness to substance P observed in SHRs is not correlated
with the elevated blood pressure. The cause of the upregulation of tachykinergic systems in
ganglia of SHRs is unknown and may be due to factors unrelated to hypertension. The question
of whether the heightened ganglion responsiveness to tachykinins contributes to the elevation of
sympathetic nerve activity and blood pressure in SHRs has not been determined. The results of
this and other studies (Dun and Karczmar 1979; Virus et al. 1981; Tsunoo et al. 1982; Lembeck
and Skofitsch 1982; Gurusinghe and Bell 1989a; Gurusinghe and Bell 1989b; Hancock and
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Lindsay 1995; Hancock and Lindsay 2000; Schoborg et al. 2000) show, however, that substance
P has actions that could contribute to the increased sympathetic nerve activity and possibly the
elevated blood pressure in SHRs.
Note in Proof
In support of our conclusions from the aforementioned experiments, we have preliminary
data that shows that preventing the development of hypertension in SHRs does not affect SCG
sensitivity to substance P (Tompkins and Hancock 2003). SHRs were prevented from developing
hypertension by chronic treatment with the angiotensin converting enzyme inhibitor captopril.
These animals (n = 3) were maintained from 6 weeks of age on drinking water containing
captopril at a concentration giving a dose of 60 mg/kg/day. Tail cuff and invasive blood pressure
values were the same as those in untreated WKY at the end of the 12 week treatment period.
External carotid nerve activity, blood pressure and heart rate responses to substance P (1.0 to 100
nmol/kg) were similar in captopril-treated SHRs and untreated SHRs. The observations that
responses to substance P in SHRs kept from becoming hypertensive are the same as in
hypertensive SHRs supports the idea that the increased sympathetic nerve response to substance
P is an inherent characteristic of SHRs and not an adaptive response of sympathetic ganglion
neurons to hypertension.
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